Compartilhar
Informação da revista
Vol. 93. Núm. 4.
Páginas 524-528 (1 julho 2018)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Visitas
5048
Vol. 93. Núm. 4.
Páginas 524-528 (1 julho 2018)
Open Access
Kaposi’s sarcoma in persons living with HIV/AIDS: a case series in a tertiary referral hospital*
Visitas
5048
Carla Andréa Avelar Pires1,2, Marcos Antonio Neves Noronha3, Julius Caesar Mendes Soares Monteiro4, Albert Luiz Costa da Costa5, José Maria de Castro Abreu Júnior6
1 Department of Clinical Medicine, Universidade Federal do Pará, Belém (PA), Brazil.
2 Department of Dermatology, Universidade do Estado do Pará, Belém (PA), Brazil.
3 Medical student, Universidade Federal do Pará, Belém (PA), Brazil.
4 Department of Clinical Medicine, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém (PA), Brazil.
5 Department of Family and Community Medicine, Centro Universitário do Pará, Belém (PA), Brazil.
6 Pathology Department, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém (PA), Brazil.
Este item recebeu

Under a Creative Commons license
Informação do artigo
Resume
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Figuras (2)
Tabelas (3)
Table 1. Distribution of persons living with HIV/AIDS and Kaposi’s sarcoma according to gender, age, current address, occupation, and conjugal status, 2004 to 2015, HUJBB, Belém, Pará State, Brazil
Table 2. Distribution of persons living with HIV/AIDS and Kaposi’s sarcoma according to time since HIV diagnosis and use of antiretroviral therapy, 2004-2015, HUJBB, Belém, Pará, Brazil
Table 3. Distribution of persons living with HIV/AIDS and Kaposi’s sarcoma according to location of skin lesions, pattern of primary lesions, and visceral involvement, 2004-2015, HUJBB, Belém, Pará, Brazil
Mostrar maisMostrar menos
Abstract
Background:

Kaposi’s sarcoma (KS) is a rare neoplasm with indolent progression. Since 1981, the Kaposi’s sarcoma epidemic has increased as co-infection with HIV.

Objectives:

The study aimed to identify the clinical and demographic characteristics and therapeutic approaches in HIV/AIDS patients in a regional referral hospital.

Methods:

We analyzed the medical records of 51 patients with histopathological diagnosis of Kaposi’s sarcoma hospitalized at Hospital Universitário João de Barros Barreto (HUJBB) from 2004 to 2015.

Results:

The study sample consisted of individuals 15 to 44 years of age (80.4%), male (80.4%), single (86.3%), and residing in Greater Metropolitan Belém, Pará State, Brazil. The primary skin lesions identified at diagnosis were violaceous macules (45%) and violaceous papules (25%). Visceral involvement was seen in 62.7%, mainly affecting the stomach (75%). The most frequent treatment regimen was 2 NRTI + NNRTI, and 60.8% were referred to chemotherapy.

Study limitations:

We assumed that more patients had been admitted to hospital without histopathological confirmation or with pathology reports from other services, so that the current study probably underestimated the number of KS cases.

Conclusion:

Although the cutaneous manifestations in most of these patients were non-exuberant skin lesions like macules and papules, many already showed visceral involvement. Meticulous screening of these patients is thus mandatory, even if the skin lesions are subtle and localized.

Keywords:
Acquired immunodeficiency syndrome
HIV
Human herpesvirus 8
Kaposi’s sarcoma
Texto Completo
Introduction

Kaposi’s sarcoma (KS) is a poorly differentiated mesenchymal neoplasm, first described in 1872 by Moritz Kaposi.1 The disease usually presents with tropism for lymphatics and blood vessels of the skin, but it can occur in other organs. There are four subtypes, with different clinical manifestations: 1) classic (Mediterranean or sporadic); 2) endemic (African); 3) iatrogenic (generally in transplant patients); and 4) epidemic (associated with HIV/AIDS).2,3

The prevalence of epidemic KS, associated with the human immunodeficiency virus (HIV), increased since the 1980s as a consequence of the spread of HIV infection. It is known as a defining disease for advanced immunodepression. The involvement of human herpesvirus-8 (HHV-8) in the etiology of all subtypes of KS was discovered in 1994.4 Today, KS is one of the most common complications of AIDS in industrialized countries. KS occurs in all age groups and mainly in men who have sex with men (MSM).5 In Brazil, there are more than 800,000 persons living with HIV/AIDS (PLWHA), and KS is the most frequent neoplasm in this group.6 Still, the etiological agent’s prevalence differs in the various populations: 1.1% in previously healthy patients, 20.4-25.9% in patients coinfected with HIV, and 75.3% in patients that are descendants of Indians from the Amazon Region.7-9

In immunocompetent individuals, the disease usually manifests more in the distal parts of limbs, while in immunosuppressed individuals KS behaves like a multifocal systemic disease.10,11 In PLWHA, studies have reported an association with other lymphoproliferative disorders such as Castleman’s disease, and this comorbidity can occur even in the presence of continuous antiretroviral therapy (cART), thus emphasizing the need for early diagnosis.12-14

Continuous ART is essential for avoiding the emergence of KS or rapid progression of the disease in PLWHA with this diagnosis.15 Continuous ART decreased the incidence of KS from approximately 30/1000 cases per patient-year to 0.03/1000 cases per patient-year.3

KS is an aggressive disease that leads to death, usually from other complications like opportunistic infections associated with AIDS.16 In a study of 112 patients with advanced immunodepression, 65 (58.0%) died from opportunistic infections and eight (7.1%) died directly from KS.17-19 This article thus aims to identify the epidemiological and clinical characteristics of persons living with HIV/AIDS and KS, admitted to a tertiary referral hospital in the Amazon Region.

Methods

A retrospective, cross-sectional case series study was performed in persons with a diagnosis of HIV-1 and concurrent histopathological diagnosis of KS from 2004 to 2015. The study group consisted of patients with histopathological confirmation of KS, treated during hospitalization in the Division of Infectious Diseases of Hospital Universitário João de Barros Barreto (HUJBB) during the study period. Inclusion criteria were: adult age (> 18 years), diagnostic confirmation of HIV-1 according to Brazilian Ministry of Health guidelines, and dermatological or endoscopic suspicion of KS with subsequent histopathological confirmation. Exclusion criteria were: patients with incomplete medical charts that prevented meeting the study protocol.

All the clinical, epidemiological, and treatment data and disease history were transcribed from the patient’s charts to the study protocol. Pathology reports were obtained from the database of the Pathology Department of HUJBB, and 113 reports were located with histopathological confirmation of KS. However, some reports referred to the same patient, when more than one biopsy had been performed to investigate KS in different organs. After exclusion of duplicates, there were 69 individuals eligible for the study. Still, 18 patient charts were not located, so 51 individuals and their respective charts were analyzed in relation to the variables age, birthplace, current address, occupation, schooling, skin color, and conjugal status. Clinical variables were classified according to the AIDS Clinical Trial Group (ACTG) guidelines for staging patients. Primary lesions were described as recorded on the medical charts, and we also analyzed the antiretroviral regimen and recorded whether the patients had been referred to chemotherapy.19

The descriptive analysis, inferences, and graphs used BioEstat 5.3, Epi Info 7, and Microsoft Excel 2010.

The study was approved by the Institutional Review Board of HUJBB, in accordance with resolution 466/2012 of the National Health Council/Ministry of Health (CNS/MS) and only began after the license was granted (case review: 787848/2014; CAE: 34639414.7.0000.0017).

One limitation to the study was possible underestimation of KS cases in the study period, since the sample only included patients with histopathological diagnosis performed at the hospital.

Results

As mentioned, of the 51 individuals, the majority were male (80.4%), ranging in age from 20 to 61 years, living in Greater Metropolitan Belém (80.4%), and single (86.3%), with hairdresser as the most frequent occupation (13.7%) (Table 1). As for time since HIV diagnosis, 58.8% had been diagnosed recently, i.e., less than six months previously (Table 2). Of these, 44 were on cART, and the mostly widely used regimen was 2 NNRTI + NRTI (70.5%).

Table 1.

Distribution of persons living with HIV/AIDS and Kaposi’s sarcoma according to gender, age, current address, occupation, and conjugal status, 2004 to 2015, HUJBB, Belém, Pará State, Brazil

Epidemiological characteristics  Absolute frequency N  Relative frequency % 
Sex     
Male  41  80.4 
Female  10  19.6 
Age (years)     
15-29  18  35.3 
30-44  23  45.1 
45-59  17.6 
≥60  2.0 
Self-reported race/skin color     
White  9.8 
Brown  44  86.2 
Black  2.0 
Not recorded  2.0 
Conjugal status     
Single  44  86.3 
Married  9.8 
Divorced  2.0 
Widow/widower  2.0 
Birthplace     
Greater Metropolitan Belém  41  80.4 
Other municipalities (counties) in Pará State  10  19.6 
Profession/Occupation     
Hairdresser  13.7 
Self-employed  7.8 
Student  5.9 
Homemaker  5.9 
Not recorded  9.8 
Other professions  29  56.9 

Source: Research protocol, 2016.

Table 2.

Distribution of persons living with HIV/AIDS and Kaposi’s sarcoma according to time since HIV diagnosis and use of antiretroviral therapy, 2004-2015, HUJBB, Belém, Pará, Brazil

Treatment characteristics  Absolute frequency N  Relative frequency % 
Time since HIV diagnosis < 6 months     
Yes  30  58.8 
No  16  31.4 
Not recorded  9.8 
Total  51  100.0 
Use of antiretroviral therapy     
Yes  44  86.3 
No  13.7 
Total  51  100.0 
Antiretroviral therapy according to classes     
2 NRTI* + NNRTI**  31  70.5 
2 NRTI + PI#  4.5 
2 NRTI + PI/rμ  15.9 
Not recorded  9.1 
Total  44  100.0 

Source: Research protocol, 2016.

*

Nucleoside reverse transcriptase inhibitor;

**

Non-nucleoside reverse transcriptase inhibitor; # Protease inhibitor; μ Ritonavir-boosted protease inhibitor.

Concerning the clinical characteristics of the disease, the majority presented disseminated skin lesions (39.2%), followed by lesions exclusively on the limbs (15.7%) and on the trunk and limbs (11.8%). The most common primary lesions were violaceous macules (40%) and violaceous papules (22.5%) (Table 3, Figures 1 and 2).

Table 3.

Distribution of persons living with HIV/AIDS and Kaposi’s sarcoma according to location of skin lesions, pattern of primary lesions, and visceral involvement, 2004-2015, HUJBB, Belém, Pará, Brazil

Clinical characteristics  Absolute frequency  Relative frequency % 
Location of skin lesions     
Face  2.0 
Face and limbs  2.0 
Oral cavity  3.9 
Neck and limbs  2.0 
Trunk  2.0 
Limbs  15.7 
Trunk and limbs  11.8 
Disseminated  20  39.2 
Not recorded  11  21.6 
Total  51  100.0 
Primary lesion     
Violaceous macules  16  40.0 
Violaceous papules  22.5 
Violaceous nodules  10.0 
Infiltrated plaques  10.0 
Violaceous tumor  5.0 
Ulcerative-vegetative lesion  12.5 
Total  40  100.0 
Visceral involvement     
Yes  32  62.7 
No  9.8 
Not reported  14  27.5 
Total  51  100.0 
Visceral organs involved     
Stomach  24  75.0 
Small intestine  25.0 
Large intestine  25.0 
Esophagus  18.8 
Lung  9.4 
Chemotherapy performed at the Oncology Service     
Yes  24  47.1 
Not referred  13.7 
Not recorded  13.7 
Death during hospitalization  13  25.5 
Total  51  100.0 

Source: Research protocol, 2016.

Figure 1:.

Oval violaceous macule, 2.5cm in diameter.

Source: Research protocol, authors’ files, 2017.

(0.32MB).
Figure 2:.

Converging violaceous papules located on anterior surface of the leg.

Source: Research protocol, authors’ files, 2017.

(0.15MB).

Nearly two-thirds (62.7%) of the individuals presented visceral involvement (n=32/51), and of these, the most frequently affected organ was the stomach (75%; n=24/32). Of all the individuals with KS, 24 (47.1%) had indication of chemotherapy after staging of the neoplastic spread to visceral organs and were accompanied by the hospital’s Oncology Department after discharge. A total of 25.5% of the individuals died in hospital.

Discussion

The study sample included a majority of adult males, with a mean age of 35 years, similar to studies from the 1990s and corroborating a more recent study in which 88% of the patients were males and with a mean age of 35 years.20-22

Concerning the profession/occupation of KS patients, several studies have shown higher incidence of the disease in individuals with more education, especially health professionals, including dentists, due to the heavy exposure to the saliva of infected patients.22-24 In the current study the most common occupation was hairdresser. Most patients had completed secondary school. One finding that stands out is the high proportion of single patients (86.3%), which raises the question concerning monogamous relationships as a protective factor, as described in the literature, and corroborating various studies on infectious diseases showing that single individuals are much more susceptible to infections from such etiological agents as herpesvirus.25

The large proportion of patients from Greater Metropolitan Belém, the state capital of Pará, is consistent with the literature reporting higher incidence of KS and HIV in the capital cities of underdeveloped countries than in the rural areas. Other regions of Pará also have regional hospitals that can receive patients from their vicinities.26 Interestingly, in urban areas of developed countries where the human development index is similar to that of undeveloped countries, there are also numerous reports of this coinfection, thus highlighting the importance of social determinants and the fact that knowledge of such determinants can help orient public policies for prevention.27

As for time since HIV infection and use of continuous antiretroviral therapy, our results corroborate other studies in the literature. In most of the cases in our study, time since HIV diagnosis was less than a year, so continuous antiretroviral therapy was also recent, which may also have resulted in early diagnosis of KS.28-30 However, this disagrees with the high percentage of visceral involvement in this patient sample. This may mean later HIV diagnosis, often made after the emergence of clinical suspicion of cutaneous KS. Early initiation of continuous antiretroviral therapy in HIV patients is known to decrease the risk of disease progression, especially with viral RNA suppression and subsequent increase in CD4 T-lymphocyte count.31,32 Treatment adherence should also be discussed at length with the patient, since lack of perfect adherence has been shown to be a risk factor (up to 20-fold) that favors dissemination of the disease and systemic manifestations.0105

Other clinical features of KS in this study were similar to those reported in the literature, with skin lesions consisting mainly of violaceous macules and papules, suggesting initial KS lesions but not necessarily the absence of visceral lesions.30,32-34 Importantly, manifestations in other organ systems can precede skin lesions.0115 In visceral involvement, the gastrointestinal tract is the most frequently affected system, especially the stomach.9,30,35

Conclusion

Although the involvement of the skin manifested in most of the cases was non-exuberant, with initial lesions like macules and papules, many of the patients had already presented visceral involvement, emphasizing the need for careful screening of patients even when skin lesions are subtle or localized. This study addressed the clinical and epidemiological characteristics of individuals with Kaposi’s sarcoma and HIV in an Amazonian population.

Financial support: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES.

Conflict of interest: None.

References
[1.]
D Costa, PCC Viana, RP Maciel, EMMS Gebrim, M.S. Rocha.
Sarcoma de Kaposi relacionado à síndrome da imunodeficiência adquirida: características do comprometimento hepático na tomografia computadorizada e na ressonância magnética..
Radiol Bras., 41 (2017), pp. 40-139
[2.]
EM Ohe, MH Padilha, MM Enokihara, FA Almeida, A.M. Porro.
Fatal outcome in classic Kaposi’s sarcoma..
An Bras Dermatol., 85 (2010), pp. 9-375
[3.]
TD Gasparetto, E Marchiori, S Lourenço, G Zanetti, AD Vianna, AA Santos.
Pulmonary involvement in Kaposi sarcoma: correlation between imaging and pathology..
Orphanet J Rare Dis., 4 (2009), pp. 18
[4.]
Y Chang, E Cesarman, MS Pessin, F Lee, J Culpepper, DM Knowles.
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma..
Science., 266 (1994), pp. 9-1865
[5.]
JW Tappero, MA Conant, SF Wolfe, T.G. Berger.
Kaposi’s sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum staging criteria and therapy..
J Am Acad Dermatol., 28 (1993), pp. 95-371
[6.]
VA Souza, LM Sumita, W Freire, HK Sato, JL Grandi, LC Pierrotti.
Prevalence of antibodies to human herpesvirus-8 in populations with and without risk for infection in São Paulo State..
Braz J Med Biol Res., 37 (2004), pp. 7-123
[7.]
VA Souza, FM Salzano, ML Petzl-Erler, MC Nascimento, P Mayaud, JD Borges J.
Variations in Human Herpesvirus Type 8 Seroprevalence in Native Americans, South America..
Emerg Infect Dis., 16 (2010), pp. 6-1003
[8.]
MC Magri, PH Carbone, E de los Santos-Fortuna, A. Caterino-de-Araujo.
A comparative study of the frequency of antibody and titers against human herpesvirus 8 latent and lytic antigens in “at-risk” individuals and among patients with Kaposi’s sarcoma..
J Med Virol., 81 (2009), pp. 7-1292
[9.]
MD Batista, S Ferreira, MM Sauer, H Tomiyama, MT Giret, CS Pannuti.
High Human Herpesvirus 8 (HHV-8) Prevalence, Clinical Correlates and High Incidence among Recently HIV-1-Infected Subjects in Sao Paulo, Brazil..
[10.]
RM Tiussi, AL Caus, LM Diniz, E.A. Lucas.
Kaposi’s Sarcoma: clinical and pathological aspects in patients seen at the Hospital Universitário Cassiano Antônio Moraes – Vitória – Espírito Santo – Brazil..
An Bras Dermatol., 87 (2012), pp. 7-220
[11.]
A. Santos.
Análise da expressão de genes selecionados do herpesvírus associado ao sarcoma de Kaposi (KSHV) em células TIVE-LTC expostas à proteína Tat do vírus da imunodeficiência humana (HIV-1) [tese]..
Universidade Estadual Paulista, (2014), pp. 73
[12.]
R Yaghoobi, N Pazyar, S. Tavakoli.
Co-existence of multicentric Castleman’s disease and Kaposi’s sarcoma..
Indian J Dermatol., 60 (2015), pp. 323
[13.]
A Pinto, J.M. Gomes.
Simultaneous lymph node involvement by Castleman disease and Kaposi sarcoma..
Rev Bras Hematol Hemoter., 33 (2011), pp. 6-73
[14.]
L Ortega, CJ Cooper, S Otoukesh, M Mojtahedzadeh, CS Didia, A Torabi.
Multicentric Castleman’s disease and Kaposi’s sarcoma in a HIV-positive patient on highly active antiretroviral therapy..
Rare Tumors., 6 (2014), pp. 98-100
[15.]
B Fonseca, V Bollela, R. Neto.
Kaposi’s Sarcoma and acquired immunodeficiency syndrome: characteristics of this association including new concepts on pathogenesis and treatment..
Medicina (Ribeirão Preto. Online)., 32 (1999), pp. 26-39
[16.]
FP Ognibene, RG Steis, AM Macher, L Liotta, E Gelmann, HI Pass.
Kaposi’s sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome..
Ann Intern Med., 102 (1985), pp. 5-471
[17.]
R. Kriggel.
The treatment and natural history of Kaposi’s Sarcoma..
Ann N Y Acad Sci., 437 (1984), pp. 53-447
[18.]
SE Krown, MA Testa, J. Huang.
AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee..
J Clin Oncol., 15 (1997), pp. 92-3085
[19.]
V Beral, TA Peterman, RL Berkelman, H.W. Jaffe.
Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection?.
[20.]
V Saraceni, CC Talhari, GF Pereira, JE Golub, S Talhari, A.E. Miranda.
AIDS-related Kaposi’s sarcoma in Brazil: trends and geopolitical distribution..
Int J Dermatol., 52 (2013), pp. 9-1525
[21.]
J Wang, J Stebbing, M. Bower.
HIV-Associated Kaposi Sarcoma and Gender..
Gend Med., 4 (2007), pp. 73-266
[22.]
J. Martin.
Kaposi Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 and Kaposi Sarcoma..
Adv Dent Res., 23 (2011), pp. 8-76
[23.]
J Ziegler, R Newton, E Katangole-Mbidde, S Mbulataiye, K DeCock, H Wabinga.
Risk Factors for Kaposi’s Sarcoma (KS) in HIV Seropositive Subjects in Uganda..
AIDS., 11 (1997), pp. 26-1619
[24.]
A Vermund, J.M. Gomes.
Combination Prevention: New Hope for Stopping the Epidemic..
Curr HIV/AIDS Rep., 10 (2013), pp. 86-169
[25.]
K Stoebenau, RC Nair, V Rambeloson, PG Rakotoarison, V Razafintsalama, R. Labonté.
Consuming sex: the association between modern goods, lifestyles and sexual behaviour among youth in Madagascar..
Global Health., 9 (2013), pp. 13
[26.]
MY Sutton, SC Gray, K Elmore, Z. Gaul.
Social Determinants of HIV Disparities in the Southern United States and in Counties with Historically Black Colleges and Universities (HBCUs), 2013-2014..
PLoS One., 12 (2017), pp. e0170714
[27.]
P. Pereira.
Investigação do antígeno nuclear latente-1 do herpesvírus humano tipo-8 no sarcoma de Kaposi epidêmico cutâneo e seus simuladores histológicos [tese]..
Fundação Oswaldo Cruz, (2011), pp. 70
[28.]
E Guttman-Yassky, M Bar-Chana, A Yukelson, S Linn, R Friedman-Birnbaum, R Bergman.
Epidemiology of classic Kaposi’s sarcoma in the Israeli Jewish population between 1960 and 1998..
Br J Cancer., 89 (2003), pp. 60-1657
[29.]
C. Lima.
Sarcoma de Kaposi: características clínico-laboratoriais, estadiamento inicial e desfecho em pacientes com aids atendidos em centro de referência de Recife/PE [tese]..
Universidade Federal de Pernambuco, (2015), pp. 107
[30.]
M, Bower, A Dalla Pria, C Coyle, E Andrews, V Tittle, S Dhoot.
Prospective Stage-Stratified Approach to AIDS-Related Kaposi’s Sarcoma..
J Clin Oncol., 32 (2014), pp. 14-409
[31.]
Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord..
Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies..
Clin Infect Dis., 63 (2016), pp. 1373-1379
[32.]
R Lupia, PB Wabuyia, P Otiato, CT Fang, F.J. Tsai.
Risk factors for Kaposi’s sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya..
J Microbiol Immunol Infect., 50 (2017), pp. 8-781
[33.]
UR Hengge, T Ruzicka, SK Tyring, M Stuschke, M Roggendorf, RA Schwartz.
Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy..
Lancet Infect Dis., 2 (2002), pp. 92-281
[34.]
TMC Corriça, MLR Caldas.
Sarcoma de Kaposi em pacientes com AIDS: estudo de 20 anos de necrópsias em Hospital Universitário..
DST- J Bras Doenças Sex Transm., 21 (2009), pp. 9-11
[35.]
R Souza, E Pozzeti, G Oliveira, N Rossi, F Ferraz, J. Antonio.
Manifestação clínica do Sarcoma de Kaposi como sinal inicial da Síndrome da Imunodeficiência Adquirida..
Arq Ciênc Saúde., 9 (2012), pp. 2-30

Work conducted at Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém (PA), Brazil. Financial support: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES. Conflict of interest: None.

Copyright © 2018. Anais Brasileiros de Dermatologia
Baixar PDF
Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
Opções de artigo
Ferramentas
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.